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IntroductIon
Atheromatosis is a lifelong, progressive disease of the 
medium- and large-sized arteries, resulting in the for-
mation of fatty and fibrous lesions in the vessel wall1. 
It’s a process that begins and develops silently dur-
ing the first decades of childhood and adolescence, 
progresses asymptomatically and generally shows no 
clinical manifestations until adulthood2,3. It is the ma-
jor cause of cardiovascular diseases leading to com-
plications such as myocardial infarction and stroke3,4. 
Atheromatosis and its complications constitute the 
main causes of death in western societies5. In the 
United States, cardiovascular disease is responsible 
for 41.4% of all deaths and constitutes the leading 
cause of mortality2.
The initiation and progressive formation of athero-
matic lesions represents a complex interplay of both 
genetic and environmental factors1,6,7. In other words 
atheromatosis and cardiovascular diseases are multi-
factorial, and their aetiopathogenesis is determined by 
genetic susceptibility and environmental factors and 
by gene-gene and gene-environment interactions8. 
Until today scientists have made enormous efforts to 
study the risk factors and signalling pathways involved 
in atheromatosis. All these approaches have led to the 
identification of numerous risk factors that lead to the 
development of atheromatosis, including cigarette 
smoking, diabetes and insulin resistance, hyperten-
sion, increased levels of circulating lipids, inadequate 
exercise and obesity9. Although several theories have 
been proposed through the last decades, none of them 
managed to explain completely the formation and 
expansion of atheromatic lesions10. In spite of this, it 
is now well accepted that atheromatosis is a chronic 
inflammatory process resulting from the interactions 
between plasma lipoproteins, various types of cells 
(macrophage, T-lymphocytes, endothelial cells and 
smooth muscle cells) and the extracellular matrix of 
the arterial wall 10, and that this process is regulated by 
an intricate network of various chemokines and cytok-
ines produced by the cells involved11,12.
In the post genomic era, the knowledge of the en-
tire reference genome sequence and some of its fre-
quent variants turned a new page in atherosclerosis 
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research concerning the study of genetic alterations. 
Whole-genome measurement technologies developed 
both in human and animal genome projects4, offer the 
opportunity to uncover entire repertoires of changes 
in gene expression related to complex diseases such 
as atheromatosis and reveal their interplay in regula-
tory networks. We already know that more than 400 
genes are involved in this process and that heritability 
estimates in humans demonstrate that genetic factors 
explain 50% of its aetiopathogenesis6. Atherogenesis-
related genes concern endothelium function, throm-
bogenesis, inflammation, lipid and carbohydrate me-
tabolism1. Despite the identification of this complicate 
network of genes, our knowledge of the roles that these 
genes play in atherogenesis still remains limited.
AtHEroMAtoSIS And cHILdrEn
Atheromatosis in children does not differ from athero-
matosis in adults. We just refer to early stage athero-
matic lesions, known as ‘‘fatty streaks’’, consisting of 
primarily macrophages and T lymphocytes10,13. In a re-
cent review Ross stated that the fatty streak in infants 
and young children is a pure inflammatory lesion and 
that this inflammation is transient and does not lead to 
major endothelial dysfunction3,14. Thus, many scien-
tists believe that a considerable number of fatty streaks 
remain unchanged or disappear during adolescence14. 
Others insist on the fact that endothelium dysfunction 
in children over time leads to measurable thickening 
of the intima and media of the vessel wall of large- 
and medium-sized arteries3. This pre-existing thicken-
ing, attracts the extracellular deposition of lipids with 
specific types of proteoglycans, and constitutes the 
earliest anatomic change of atherosclerosis which will 
finally result in advanced fibrous atheromatic lesions 
observed in adults15.
Over the last 20 years there are numerous stud-
ies detecting atherosclerotic lesions in the coronary 
arteries of children and adolescents and demonstrat-
ing the early onset of this disease2. Until recently, our 
understanding of the childhood antecedents of adult 
atherosclerosis and cardiovascular disease was lim-
ited, having been based on autopsy studies of patho-
logic findings in teens and young adults who died of 
accidental causes. However, recent development of 
new technologies has made it possible to detect early 
anatomic and physiologic changes in children3,16. Ob-
servations from the Bogalusa Heart Study have shown 
that atheromatosis major risk factors of adults are pres-
ent in childhood and adolescence17, with documented 
anatomic changes as early as 5 to 8 years of age3,18.
Non-invasive functional and structural tech-
niques19 are now available and provide the opportu-
nity to characterize early arterial disease long before 
cardiovascular complications present. By using these 
techniques, it has been possible to quantify the impact 
of conventional and novel cardiovascular risk factors 
seen in childhood on the development of preclinical 
atherosclerotic changes18, but also to reveal the gene-
gene and gene-environment complex interactions that 
regulate the expression of these genes.
rESEArcH MEtHod
We performed a computer-based search using the Pub 
Med database with the following search terms: genes 
+ early atheromatosis, risk factors + early atheroma-
tosis, fatty streaks, cardiovascular disease + children, 
inflammation + atheromatosis + children, lipid me-
tabolism + atheromatosis + children. References from 
the retrieved articles were also screened for additional 
papers. We reviewed all association studies and publi-
cations in English until September 2008.
InFLAMMAtIon  
And AtHEroMAtoSIS In cHILdrEn
Atheromatosis is predominantly an inflammatory 
condition produced by a “response to injury”20, and 
atheromatic lesions, from fatty streak to advanced fi-
brous lesions and the final plaque rupture, possess all 
features of chronic inflammation7,10,20,21,22. In general, 
an inflammatory response is a normal physiological 
reaction to daily encountered micro-organisms, tissue 
damage, and modified self-proteins in an attempt of 
the body to restore and maintain homeostasis21. The 
immunopathogenesis of atherosclerosis involves a 
complex interaction between various leukocyte sub-
sets, platelets, endothelial cells, and vascular smooth 
muscle cells23. It is now well accepted that a complex 
endothelial injury and dysfunction induced by a va-
riety of factors including homocysteine, toxins such 
as smoking, shear stress, infectious agents, hyperten-
sion, hyperglycaemia and oxidized low-density lipo-
protein (oxLDL), results in an inflammatory response 
that is crucial in the initiation and further progression 
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of atheromatic lesions7,10,24. This response to injury, 
with the following lipid migration and expression 
of surface adhesion molecules7, results in a cascade 
of immunological mediated events characterized by 
the production of a wide range of chemokines (Ccl2, 
Ccl9, Ccl11, Ccl19, Ccl21, Cxcl1 και Cxcl2), cytok-
ines (IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, INF-γ and 
TNF), and growth factors (VEGF)11,12,21,25. The role 
of inflammation in atherogenesis is confirmed by im-
munohistochemical studies, both in fatty streaks of 
mice and human, where several cytokines and inflam-
matory cells (monocyte-derived macrophages and T-
lymphocytes) have been found10,13,20.
Recent research has demonstrated even stronger 
evidence of the relationship between inflammation 
and endothelial dysfunction, and numerous systemic 
markers of inflammation, such as C-reactive protein 
(CRP) and homocysteine have been associated with 
the initiation of atheromatosis3,7,8. Beyond represent-
ing inflammatory markers, these factors have pro-
atherogenic functions. Most notably, CRP has been 
reported to induce expression of leukocyte adhesion 
molecules, tissue factors, monocyte recruitment to ar-
terial wall with the induction of MCP-1, and increased 
complement activation7. An elevated CRP level even 
among healthy children has been shown to be associ-
ated with a reduction in endothelial function3. On the 
other hand, experimental studies have shown that el-
evated plasma homocysteine levels may promote the 
initiation of atheromatosis in different ways8. Hyper-
homocysteinaemia is believed to promote endothelial 
damage and dysfunction by inhibiting nitric oxide 
synthase and subsequently decreasing the bioavail-
ability of nitric oxide8. Also, hyperhomocysteinaemia 
might activate platelets, and thus increase platelet ag-
gregation and adhesion, and can impair DNA methy-
lation affecting both the expression of endothelial and 
smooth muscle cells. In that way elevated plasma ho-
mocysteine levels induce smooth muscle cells prolif-
eration leading to luminal narrowing8. Finally, excess 
homocysteine may initiate atheromatosis through NF-
κB induction8.
One of the key regulators of inflammation is the 
transcription nuclear factor-κB (NF-κB), which is ac-
tually a family of transcription factors consisting of 5 
members: p65 (RelA), c-Rel, RelB, NF-κB1 (p50 and 
its precursor p105), and NF-κB2 (p52 and its precur-
sor p100)21. NF-κB is believed to regulate more than 
160 genes, some of them involved in the early stages 
of atheromatosis21. Those genes are related to inflam-
matory and immunologic pathways, apoptosis and 
cell proliferation and thus for a long time NF-κB has 
been regarded as a pro-atherogenic factor mainly be-
cause of the regulation of various pro-inflammatory 
genes11. In details, NF-κB regulates the transcription 
of several enzymes important in the early modifica-
tion of LDL and the formation of inflammatory lipid 
mediators21. Also NF-κB controls the transcription of 
monocyte chemoattractant protein-1 (MCP-1), a sig-
nificant chemokine for the attraction of monocytes 
in early lesion development and of several adhesion 
molecules, including P-selectin, E-selectin, intercel-
lular adhesion molecule-1 (ICAM-1), and vascular 
cell adhesion molecule-1 (VCAM-1), all implicated 
in the initiation of atheromatosis21. The crucial role 
of this factor in atherogenesis was finally established 
by experiments showing that NF-κB was highly ex-
pressed in endothelial cells of regions prone to devel-
oping atherosclerotic lesions compared to the cells of 
regions that were less prone21.
During the last decade, studies in animal models 
have established cytokines and chemokines as pivotal 
players in the regulation of endothelial and smooth 
muscle cell (SMC) function13. Thus, it is now accepted 
that apart from their potent effects on immune system 
and inflammatory cells, these molecules also promote 
endothelial cell dysfunction and alter SMC phenotype 
and function, which can contribute to or retard vas-
cular pathologies13. Cytokines and chemokines can 
also significantly enhance the function of endothelial 
cell adhesion molecules at all stages of transendothe-
lial cell migration13. Also someone should emphasize 
on the fact that many cytokines, such as tumor ne-
crosis factor-α (TNF-α), can possibly induce a num-
ber of other cytokines and chemokines13. According 
to in vitro studies, pro-inflammatory factors such as 
interferon-gamma (IFN-γ), TNF-α and interleukin-1 
beta (IL-1β), can be atherogenic by impairing re-
verse cholesterol transport system (RCT), a pathway 
through which accumulated cholesterol is transported 
from the vessel wall to the liver for excretion, thus 
preventing atherosclerosis26. IL-1 has been studied 
in atherogenesis using either IL-1β-deficient mice or 
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mice with lack of the IL-1 receptor. Absence of IL-
1β in apoE–/– mice reduced atheromatosis by almost 
30% and this effect was accompanied by a significant 
decrease in the expression of one of the major adhe-
sion molecules in the early stages of atheromatosis, 
VCAM-1, and chemokine MCP-121. The expression 
of VCAM-1, which binds predominantly monocytes 
and T lymphocytes, is also induced by many pro-in-
flammatory cytokines such as TNFα and IL-627. En-
dothelial cell dysfunction is also promoted by INF-γ 
and experiments have already shown that blockade 
of this pro-inflammatory cytokine inhibits athero-
genesis13. In contrast there are some cytokines which 
retard lesion formation13. The absence of the anti-in-
flammatory cytokine IL-10 has also been evaluated 
in mice and this interleukin shows inhibitory activity 
for SMC recruitment, and its action may counteract 
the pro-atherogenic activity of other cytokines ob-
served in fatty streaks13. Except for IL-10, IL-18 also 
appears to negatively regulate SMC proliferation in 
early atheromatic lesions13. Finally IL-10 and TGF-β 
can notably inhibit NF-κB’s pro-inflammatory signal-
ling pathway, and thus prevent atherogenesis13. It is 
clear that cytokine stimulation of endothelial cells can 
both positively and negatively modulate expression of 
endothelial gene products and regulate the process of 
atheromatosis.
Previous studies have already shown that elevated 
myeloperoxidase (MPO) levels were associated with 
the presence of coronary heart disease28. MPO is con-
sidered to be pro-atherogenic due to the inflammatory 
effects that possesses. Mutations on the MPO gene, 
such as the -463G/A polymorphism, can have a func-
tional significance and lead to higher reactive oxygen 
species (ROS), which finally results in the formation 
of early lesions28.
Fetuin-A (AHSG), is a liver-secreted, plasma gly-
coprotein whose biological function remained obscure 
until recently. We already know that AHSG inhibits 
ectopic calcification and can act as a natural inhibi-
tor of the insulin receptor tyrosine kinase in liver and 
skeletal muscle29. It was recently reported that AHSG 
suppresses atheroprotective adiponectin production 
and generates an atherogenic profile of lipoproteins 
which results in the induction of several inflamma-
tory cytokines29. All these alterations affect significant 
pathways of atherogenesis and lead to the early ‘‘fatty 
streaks’’ formation.
Children’s obesity is reaching alarming propor-
tions and is considered to be a major health problem. 
World Health Organization estimates that there are 3 
millions obese children in Europe and this huge num-
ber is raised by 85.000 more children every year30. 
Obesity represents a chronic inflammatory status and 
obese children of all ages have evidence of a low-
grade chronic inflammatory state2,31. Adipocytes re-
lease either cytokines or an array of adipokines such 
as leptin, which regulate immunologic and systemic 
activities32. There have been numerous studies as-
sociating child obesity with various changes in lipid 
profile and inflammatory markers, and thus scientists 
believe not only that this status might accelerate ather-
omatosis and cardiovascular disease later on, but may 
also be associated with the initiation of atheromatosis 
in early life3,18,31,33. In details, the involvement of cy-
tokines in obesity as well as of the adipokine leptin 
is supported by studies showing that weight reduc-
tion normalizes mediators of inflammation. In fact, 
absolute numbers of CD4+ cells and CD4/CD8 ratio 
increase, while leptin values fluctuate within normal 
ranges, after a hypocaloric diet for a six month peri-
od32. The correlation of circulating CRP, inflammatory 
cytokines and complications of obesity has been stud-
ied in obese children with mixed results. There have 
been large population studies showing that body mass 
index (BMI) is the best predictor of elevated CRP in 
children3. Elevated levels of serum TNF-α have been 
found in some studies of obese children although there 
are also studies showing no correlation between obe-
sity and this inflammatory marker. Finally, IL-6 and 
adiponectin were positively and negatively correlated 
with BMI respectively31.
An important goal of future studies will be a more-
detailed investigation of all genes and inflammatory-
related pathways regulated by different cytokines in 
atherogenesis. The relatively recent appreciation that 
inflammatory response plays a key role in atherogen-
esis implies that inhibiting inflammation may provide 
new anti-atherosclerosis therapy.
LIPId MEtABoLISM
Intracellular processes that regulate lipid metabolism 
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are crucial for our health status both in childhood and 
adulthood, but our understanding of lipid homeostasis 
is limited because of the complexity that character-
izes their metabolic pathways involving cholesterol 
uptake, biosynthesis, transport, metabolism, and se-
cretion26. The role of cholesterol in atheromatosis is 
well established and has been elegantly reviewed34 
and hypercholesterolemia is an independent risk fac-
tor in early atheromatosis well described and docu-
mented even 20 years ago3,35. Excess on cholesterol 
blood levels results in atherogenesis through early 
endothelial activation or dysfunction accompanied by 
the expression of adhesion molecules and chemok-
ines10. In details, it has been demonstrated that oxi-
dized low-density lipoprotein (LDL), remnant lipo-
protein (β-VLDL) and lipoprotein-a (LPa) play a 
critical role in the pro-inflammatory reaction and the 
formation of early stage lesions and are considered 
to be atherogenic when elevated in the plasma10. El-
evated blood levels of these lipoproteins up-regulate 
vascular cell adhesion molecule-1 (VCAM-1), intrac-
ellular adhesion molecule-1 (ICAM-1), P-selectin and 
E-selectin, molecules considered to be responsible 
for the adherence of macrophages and T-lymphocytes 
to endothelium10. After the deposition in the intima, 
these lipoproteins are subjected to chemical modifi-
cation leading to a series of biological reactions, as 
mentioned above10. A recent study showed that low-
ering plasma cholesterol eliminates the formation of 
atheromatic lesions observed in mice with sustained 
high levels of plasma cholesterol4 and that the mRNA 
levels of thirty-seven atherosclerosis genes responded 
strongly to this cholesterol lowering4. Beyond that, 
there is recent evidence that lipids and lipoproteins 
may act as nuclear factors affecting basic biological 
phenomena such as transcription, genome stability, 
and cell differentiation. In particular, experimental 
studies provide new insights into the mechanisms of 
interaction between DNA and lipid molecules such as 
short-chain fatty acids and cholesterol and it has been 
shown that hyperlipidaemic lipoprotein profiles are 
associated with aberrant DNA methylation patterns at 
early stages of atheromatosis in mice and in cultured 
human macrophages, suggesting that a rearrangement 
of DNA methylation patterns is among early molecu-
lar changes associated with atherogenesis36.
Familial hypercholesterolemia (FH) is the most 
common lipid disorder in childhood affecting 1 out 
of 500 individuals and the frequency of homozygotes 
is about 1:1,000,00037. FH is a dominantly inherited 
autosomal disorder caused by mutations of the low-
density lipoprotein receptor (LDLR) gene on chro-
mosome 1937,38. LDLR is a cell- surface glycoprotein 
responsible for the uptake and catabolism of plasma 
LDL. The defective protein fails to catabolize LDL 
particles causing higher concentrations of total cho-
lesterol (TC) and LDL cholesterol (LDL-C) in the 
plasma39. More than 600 different mutations have 
been described in the literature so far37. Some of the 
LDLR variants which were already reported to play a 
significant role in early atheromatosis are C201-D206, 
C297F, G528D, Q81X, C358R, D97Y, G571E and a 
recent study discovered three new missense mutations 
G266C, T368M, and D451Y on exons 6, 8 and 10 of 
the LDLR gene respectively39.
Lipoprotein(a) or LP(a), is a member of the plas-
ma lipoproteins with general properties of LDL and 
high LP(a) plasma levels have been associated with 
an increased incidence of cardiovascular disease, due 
to both atherogenic and thrombogenic potentials of 
this molecule40. In particular, studies in animal mod-
els showed that LP(a) may act as a pro-inflammatory 
agent that accelerates early lesion formation10 and 
thus represents an independent predictor of the de-
velopment of premature atherosclerosis in humans41. 
The LP(a) particle consists of two disulfide-linked 
proteins, apolipoprotein B (APO-B) and APO(a). The 
APO(a) is a highly glycosylated protein and there have 
been reported more than 20 genetic polymorphisms in 
this molecule related to early atheromatic lesions43. 
APO-B measured in children and adolescents, reflects 
a lipoprotein profile predisposing to the development 
of subclinical atherosclerosis and is considered to be a 
marker which might have value in paediatric lipid risk 
assessment42. Also, familial deficiency of APO-B 100 
is an autosomal dominant disorder related to hyper-
lipidaemia and premature atheromatosis in children42. 
Among the genetic alterations associated with lipid 
metabolism, the APO-E genotype has gained particu-
lar prominence within the problem of early atheroma-
tosis. This is a polymorphic gene with 3 co-dominant 
alleles (ε 2, ε 3, ε 4) that give rise to 6 genotypes: ε 
2ε 2, ε 2ε 3, ε 3ε 3, ε 3ε 4, ε 4ε 4 and ε 2ε 4. Sev-
eral population studies have shown that the ε 4 al-
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lele, and in particular the ε 3ε 4 genotype, is strongly 
associated with early atheromatosis and fatty streak 
formation2,42.
A critical part of RCT, which was previously men-
tioned, is cholesterol efflux, in which accumulated 
cholesterol is removed from macrophages of the vessel 
wall with the ATP-binding membrane cassette trans-
porter A1 (ABCA1) or other mechanisms (SR-B1, ca-
veolins, sterol 27-hydroxylase) and collected by HDL 
and apoA-I26. This cholesterol-HDL molecule is then 
delivered to the liver for excretion. ABCA1 is an inte-
gral membrane protein which facilitates cellular cho-
lesterol efflux and has generated considerable interest 
as a potential anti-atherogenic agent. In patients with 
mutated ABCA1 genes, RCT and cholesterol efflux 
are impaired and atheromatosis is increased. In stud-
ies with transgenic mice, disruption of ABCA1 genes 
can induce atheromatosis26. Other studies with animal 
models showed that mice, strongly expressing AB-
CA1, exhibit an anti-atherogenic lipid profile, with el-
evated levels of HDL-C and apoA-I, and significantly 
less aortic atherosclerosis26. Mutation of this gene in 
humans is the genetic cause of Tangier disease (TD), 
an autosomal recessive disorder of lipid metabolism 
associated with cardiovascular disease19,26. In TD, fi-
broblasts, HDL-mediated cholesterol efflux and intra-
cellular lipid trafficking and turnover are abnormal, so 
these patients have low levels of HDL and high levels 
of triglycerides26.
Cholesterol ester transfer protein (CETP) is a mol-
ecule that facilitates the transport of cholesteryl ester 
from HDL to APO B-containing lipoproteins. These 
cholesteryl esters are then delivered back to the liver 
via LDLR, and finally eliminated through the gastro-
intestinal tract26. Recent studies in transgenic mice 
have already shown that the introduction of the hu-
man CETP gene with an atherogenic diet results in 
decreased HDL levels, increased VLDL, LDL and 
APO B levels and finally initiates the formation of 
spontaneous atheromatic lesions, supporting the hy-
pothesis that CETP is pro-atherogenic26. In humans, 
a decrease of CETP activity may increase HDL and 
decrease VLDL and LDL and CETP inhibition has at-
tracted scientists’ attention26. JTT-705 is a direct in-
hibitor of CETP that raises HDL in a dose-dependent 
manner and also a CETP vaccine is manufactured, 
which induces auto-antibodies that specifically bind 
and inhibit endogenous CETP, with the intention of 
increasing HDL and reducing the development of 
atheromatosis26.
Thus, it is clear that identifying the genetic deter-
minants of dyslipidemia and all the pathways involved 
in lipid metabolism is a crucial step towards under-
standing the molecular basis of early atheromatosis 
and developing new therapeutic approaches.
MMPs
It is widely accepted that oxLDL promotes athero-
genic events which are in part mediated by matrix 
metalloproteinases (MMPs), inflammatory cytok-
ines, and prostaglandins, produced and secreted from 
all kinds of cells involved in atheromatic process43. 
Among these mediators, MMPs are zinc-dependent 
endoproteinases that participate in the remodelling 
of the extracellular matrix (ECM)44. The isozymes of 
MMPs identified to date have been classified into 5 
groups including collagenases (MMP-1, -8, and -13), 
gelatinases (MMP-2 and -9), stromelysins (MMP-3, 
-10, and -11), membrane-type MMPs (MMP-14, -15, 
-16, -17, -24, and -25), and matrilysins (MMP-7 and 
-26). MMPs are believed to play an important role 
in every stage of atheromatosis and numerous stud-
ies have already shown that MMP-1, -2, -3, -7, -8, -9, 
-12, -13, and -14 are highly expressed at atheromatic 
lesions43,45. Among them, MMP-9, MMP-3 and MMP-
12 seem to act as atherogenic agents43,45,46. MMP-9 is 
involved in the development and progression of ather-
omatosis43 and studies in MMP-9-deficient SMC and 
MMP-9 knockout mice showed that this MMP-9 de-
ficiency resulted in decreased migratory activity, less 
intima hyperplasia and finally less atheromatosis44. 
The function of MMP-12 in the initiation of athero-
matosis was studied in human MMP-12 transgenic 
(Hmmp-12 Tg) rabbits46. Fatty streaks in hMMP-12 
Tg rabbits fed a 1% cholesterol diet for 6 weeks (cho-
lesterol-induced model of atherosclerosis) were more 
pronounced and were associated with more significant 
degradation of the internal elastic layer compared with 
wild-type (WT) animals. Also the numbers of infiltrat-
ing macrophages and smooth muscle cells in the le-
sions were increased in hMMP-12 Tg compared with 
WT animals46.
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Thus, the elucidation of the role of other MMPs 
variants will permit a better understanding of the 
events observed in the early stage of atheromatosis and 
will potentially result in new therapeutic approaches.
otHEr rISK FActorS  
oF AtHEroMAtoSIS In cHILdrEn
Apart from all the genetic components of the early 
stage of atheromatosis which were previously de-
scribed, scientists have identified even more agents 
believed to interfere in atherogenesis:
Group IIA phospholipase A2 (secretory PLA2 or sP-
LA2) has been found in human atherosclerotic lesions 
and is implicated in chronic inflammatory conditions 
such as atheromatosis24. sPLA2 IIA is considered to 
be a pro-atherogenic factor and has been suggested to 
regulate collagen deposition in the plaque and fibrotic 
cap development24.
Sphingomyelinase (SMase) is an enzyme that hy-
drolyzes sphingomyelin (SM) to release ceramide, a 
substance which is elevated in atherosclerotic plaques 
as well as in LDL isolated from these lesions. Cer-
amide is believed to play a crucial role in the early 
accumulation of LDL within the arterial wall, which is 
a critical step in the initiation of atheromatosis24.
AMPK is a protein kinase, whose activation re-
presses the proliferation of many cells involved in 
atherogenesis and also regulates the expression of 
genes related to lipid metabolism 45. AMPK’s signal-
ing pathway involves a significant number of tumor 
suppressing genes (LKB1, p53, TSC1 and TSC2) and 
enhances various growth factors45. Thus, this molecule 
might be used as a therapeutic agent in atherogenesis 
through inhibiting the proliferation of the cells partici-
pating in early formation of atheromatic lesions.
Considering atheromatosis to be a metabolic com-
plication has directed scientists’ attention towards 
peroxisome proliferator-activated receptors (PPARs). 
PPARs, as ligand-activated transcription factors be-
longing to the nuclear hormone receptor family, can 
regulate multiple target genes. Extensive data estab-
lish expression of all three PPAR isotypes (PPARα, 
-γ, and -δ/β) throughout the vasculature and inflam-
matory cells27 and the potential importance of these 
factors in atheromatosis is evident by their transcrip-
tional regulation of pathways involved in atherogenic 
dyslipidemia, extracellular matrix remodeling, cho-
lesterol efflux, thrombogenicity, and inflammation27. 
As such, PPARs may well be involved in all stages 
of atheromatosis, from the earliest fatty streaks to the 
late stage complicated lesions27. In details, PPARα is 
believed to play an important role in atherogenesis 
by reducing leukocyte adhesion to activated endothe-
lial cells and inhibiting subsequent transendothelial 
leukocyte migration27. Also this receptor exerts anti-
inflammatory effects in the vascular wall through a 
decrease in the expression of inflammatory cytokines 
such as IFN-γ, TNFα, and IL-2. PPARα inhibits the 
expression of NF-κB21 and improves lipid profile by 
reducing triglycerides levels and increasing HDL lev-
els27. Finally, PPARγ in SMC suppresses the expres-
sion of genes responsible for the adhesion of mono-
cytes to the endothelium (VCAM-1, ICAM-1) and 
their transendothelial migration, which are both cru-
cial early processes for the subsequent development 
of atheromatic lesions47.
dnA MEtHYLAtIon  
And AtHEroMAtoSIS In cHILdrEn
Gene expression can be regulated at a genetic level by 
structural changes in DNA sequence and at an epige-
netic level by mechanisms that are mutation indepen-
dent. This epigenetic regulation of gene expression 
involves modifications of chromatin such as DNA 
methylation and several types of histone post-transla-
tional modifications such as acetylation, methylation, 
phosphorylation, and ubiquitination48. DNA methyla-
tion is the post-replication addition of methyl groups 
to the 5’ position of cytosine rings within the context 
of CpG dinucleotides9. P. E. Newman was the first 
scientist that made the hypothesis that aberrant DNA 
methylation patterns play a key role in atherogenesis49. 
Since late 1990s the study of DNA methylation pro-
gressed and researchers started to reveal the relation-
ship between this epigenetic modification and various 
genes involved in the process of atheromatosis. These 
studies show that the initial stages of atheromatosis 
are associated with a rearrangement of genomic DNA 
methylation patterns including both hyper- and hypom-
ethylation, of atheromatosis-protective and atheroma-
tosis-susceptible genes respectively48. For example 
DNA hypermethylation at the human estrogen recep-
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tor gene (ERα) is associated with early atheromatosis 
and also genes related to lipid metabolism are likely 
candidate factors behind such changes48. Despite re-
markable progress, the study of DNA methylation in 
atheromatosis is still at the beginning. With the advent 
of new technologies, it is possible that in the future we 
will be able to analyze and understand epigenotype-
phenotype relationships, which may unravel an epige-
netic mechanism underlying atherogenesis.
GEnE-EnVIronMEnt IntErActIonS
So far, we have mentioned all those genes and their 
variants believed to be involved in atherogenesis and 
the formation of fatty streaks in children. Beside this 
intricate network of genes and their interactions, gene-
environment interactions might also play a significant 
role in early atheromatosis, given the fact that gene 
expression is partially regulated by environmental 
factors.
In general, evidence based on human epidemio-
logical studies and dietary interventions in animal 
models, suggest that maternal nutritional imbalance 
and metabolic disturbances during gestation and fe-
tus development may have a persistent effect on the 
health of the offspring and may even be transmitted 
to the next generation50,51. In the last decade a series 
of studies have demonstrated that common disorders 
take root in early nutrition and thus, Hales and Barker 
first introduced the term ‘‘fetal programming’’52. The 
fact that early atheromatic lesions are already formed 
during fetal development was first documented 25 
years ago53 and it is widely recognized that the uterus 
environment determines significantly adult disease54. 
Recent research, links dysmetabolic conditions dur-
ing pregnancy with increased atheromatosis in child-
hood and scientists focus on the impact of specific 
maternal risk factors, such as obesity, metabolic syn-
drome, and diabetes, on cardiovascular risk in the off-
spring54. As previously mentioned inflammation plays 
a crucial role in atherogenesis, and two key factors 
that influence inflammation, maternal hypercholester-
olemia and maternal immune mechanisms, have been 
shown to affect the developmental programming of 
early atheromatosis. Maternal hypercholesterolemia 
during pregnancy is associated with increased fatty 
streak formation in human fetal arteries and acceler-
ated postnatal atherogenesis in normocholesterolemic 
children53,54. Gene expression between offspring of 
normo- and hypercholesterolemic mothers differs, 
and these differences persist long after birth, sup-
porting the assumption that fetal lesion formation is 
associated with genetic programming53. On the other 
hand CRP level during gestation is believed to be an 
important predictor of increased atherogenesis in off-
spring of hypercholesterolemic mothers55. Finally, an-
other study relates early atheromatosis in 9 year-old 
children, as measured by intima media thickening, 
with a lower energy intake of mothers during preg-
nancy, reinforcing the idea that maternal nutritional 
condition might influence susceptibility to childhood 
atheromatosis51.
Not only the in utero nutritional status but also 
postnatal diet is believed to program early atheroma-
tosis in children. This assumption was based on post-
natal nutritional manipulations in animal models and 
human epidemiological data that relate markers of 
early nutrition, such as the size of birth or in infancy, 
to atherogenesis56. For example in one epidemiologi-
cal study, scientists associated prolonged breast-feed-
ing with a greater incidence of atherosclerosis in adult 
life56. Also there are numerous studies concerning the 
identification and characterization of genes regulated 
by the level of dietary fat, and researchers demon-
strated that the expression of Lfm-1 and Lfm-2 genes, 
which are associated with atheromatosis, changed in 
relation to different levels of fat intake57. Thus, read-
justing our early nutritional policies might result in 
a better nutritional programming and prevention of 
atheromatosis and cardiovascular disease.
FuturE PErSPEctIVES
Atheromatosis in children and adolescents is really a 
reversible process and anatomic changes observed in 
early atheromatosis are modifiable3,18. Thus, primary 
prevention strategies beginning in childhood have 
great potential and might result in prevention of adult 
cardiovascular disease. Several guidelines have been 
already published16,18 and some of the recommended 
measures are low-fat diets and regular high-energy 
exercise to prevent children’s obesity, screening of 
blood pressure, lipid profile and glucose levels and 
finally pharmacologic intervention in case our targets 
cannot be achieved in any other way3,14,16. The identifi-
cation of atheromatosis susceptible genes with the use 
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of candidate gene approach and genome-wide linkage 
studies1, have been very useful in shedding light on 
this complex disease. Advances in statistical analysis 
and bioinformatics as well as the development of new 
methods such as array analysis, suppression subtrac-
tive hybridization (SSH) and cDNA representational 
analysis, provide scientists the ability to study the 
expression level of thousands of genes and uncover 
the intricate gene-network of atheromatosis58,59,60. Af-
ter all, discovering these genes and unravelling their 
gene-gene and gene-environment interactions is a 
crucial step in order to facilitate drug target develop-
ment. Gene therapy for atheromatosis and subsequent 
cardiovascular disease is in progress although, neither 
interference of target gene expression nor the transfer 
of therapeutic genes is clinically used61. The relative 
accessibility of blood vessel and myocardium makes 
them ideal targets for gene therapy and we have al-
ready obtained encouraging results with genes encod-
ing growth factors (VEGF), transcriptional factors 
(NF-κB) and inherited genetic defects in lipid metabo-
lism such as familial hypercholesterolemia61.
In the future, it may be possible that administering 
a single genetic test will be adequate to reveal patients 
likely to develop atheromatosis and cardiovascular 
disease. Until then, more research is required in order 
to unravel the full genetic repertoire of this complex 
process.
ΠΕΡΙΛΗΨΗ: Η αθηρωμάτωση αποτελεί μία χρόνια εξελισσόμενη πάθηση των μέσου και μεγάλου μεγέθους αγγείων, η 
οποία ξεκινά σιωπηρά κατά την περίοδο της εμβρυικής ανάπτυξης, εξελίσσεται κατά την παιδική και εφηβική ηλικία και 
εκδηλώνεται κλινικά κατά την ενήλικο ζωή. Αιτιοπαθογενετικά αποτελεί μία πολύπλοκη διαδικασία, στην γένεση και την 
εξέλιξη της οποίας συμμετέχουν τόσο γενετικοί όσο και περιβαλλοντικοί παράγοντες. Μέχρι σήμερα έχουν πραγματοποιηθεί 
πολυάριθμες μελέτες με σκοπό την ανίχνευση αθηρωματικών ελκών στις στεφανιαίες αρτηρίες των παιδιών και εφήβων, απο-
δεικνύοντας την πρώιμη έναρξη της νόσου. Αν και η έρευνα για την ανακάλυψη του συνόλου των γονιδίων που συμμετέχουν 
στην διαδικασία της αθηρωγένεσης δεν έχει ολοκληρωθεί, εντούτοις έχουν ήδη γίνει τα πρώτα βήματα για την κατανόηση 
της μοριακής βάσης της παιδικής αθηρωμάτωσης. Στην αιτιοπαθογένεια της πολύπλοκης αυτής διαδικασίας εμπλέκεται ένας 
μεγάλος αριθμός γονιδίων που σχετίζονται με την φλεγμονή, τον μεταβολισμό των λιπιδίων, τις μεταλλοπρωτεάσες αλλά και 
πλήθος επιγενετικών τροποποιήσεων και αλληλεπιδράσεων μεταξύ γονιδίων και περιβάλλοντος. Η πρώιμη αθηρωμάτωση 
αποτελεί μία αναστρέψιμη διαδικασία και για τον λόγο αυτό με την σωστή οργάνωση στρατηγικών πρόληψης από την παιδική 
ηλικία, μπορεί να επιτευχθεί η πρόληψη των καρδιαγγειακών παθήσεων κατά την ενήλικο ζωή.
Λέξεις Κλειδιά: Αθηρωγένεση, Παιδική αθηρωμάτωση, Πρώιμη αθηρωμάτωση.
Μοριακή βάση της παιδικής αθηρωμάτωσης.
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